BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND CRTC1, Q6UUV9, 23373, ENSG00000105662, KIAA0616, TORC1, MECT1, WAMTP1, FLJ14027
26 results:

  • 1. MED15::ATF1-Rearranged tumor: A Novel Cutaneous tumor With Melanocytic Differentiation.
    Ko JS; Lemahieu J; Billings SD; Tirode F; Payton D; Boone B; Pissaloux D; de la Fouchardiere A
    Mod Pathol; 2024 Apr; 37(4):100438. PubMed ID: 38278485
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Cutaneous melanocytic tumor with crtc1::TRIM11 fusion: a case report.
    Duan R; He X; Ma X; Huang F; Hu X
    Diagn Pathol; 2024 Jan; 19(1):8. PubMed ID: 38184586
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. One step at a time: Melanocytic differentiation in fusion-driven cutaneous neoplasms.
    Linos K
    J Cutan Pathol; 2023 Dec; 50(12):1116-1118. PubMed ID: 37844955
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Cutaneous Melanocytic tumor With crtc1::TRIM11 Translocation : An Emerging Entity Analyzed in a Series of 41 Cases.
    Hanna J; Ko JS; Billings SD; Boivin F; Beaudoux O; Pissaloux D; Tirode F; Laga A; Fletcher CDM; de la Fouchardiere A
    Am J Surg Pathol; 2022 Nov; 46(11):1457-1466. PubMed ID: 35993578
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Regulation of torc1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain tumor Models.
    Li F; Bondra KM; Ghilu S; Studebaker A; Liu Q; Michalek JE; Kogiso M; Li XN; Kalapurakal JA; James CD; Burma S; Kurmasheva RT; Houghton PJ
    Clin Cancer Res; 2022 Sep; 28(17):3836-3849. PubMed ID: 35797217
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Dermal melanocytic tumor with crtc1-TRIM11 fusion: Report of two additional cases with review of the literature of an emerging entity.
    Parra O; Bridge JA; Busam KJ; Shalin SC; Linos K
    J Cutan Pathol; 2021 Jul; 48(7):915-924. PubMed ID: 33586183
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. torc1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma.
    Maynard RE; Poore B; Hanaford AR; Pham K; James M; Alt J; Park Y; Slusher BS; Tamayo P; Mesirov J; Archer TC; Pomeroy SL; Eberhart CG; Raabe EH
    Cancer Lett; 2021 Apr; 504():137-145. PubMed ID: 33571541
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Stem cell Factor-Inducible MITF-M Expression in Therapeutics for Acquired Skin Hyperpigmentation.
    Yun CY; Roh E; Kim SH; Han J; Lee J; Jung DE; Kim GH; Jung SH; Cho WJ; Han SB; Kim Y
    Theranostics; 2020; 10(1):340-352. PubMed ID: 31903124
    [No Abstract]    [Full Text] [Related]  

  • 9. Synergistic activity of mtorc1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity.
    Arnold A; Yuan M; Price A; Harris L; Eberhart CG; Raabe EH
    Neuro Oncol; 2020 Apr; 22(4):563-574. PubMed ID: 31841591
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. A case report of cutaneous melanocytoma with crtc1-TRIM11 fusion: Is CMCT distinct from clear cell sarcoma of soft tissue?
    Kashima J; Motoi T; Nishimaki M; Hayashi Y; Ogawa M; Kato I; Yamada R; Tonooka A; Horiguchi SI; Funata N; Hishima T; Yoshino K
    Pathol Int; 2019 Aug; 69(8):496-501. PubMed ID: 31276279
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Ceritinib Enhances the Efficacy of Trametinib in
    Verduzco D; Kuenzi BM; Kinose F; Sondak VK; Eroglu Z; Rix U; Smalley KSM
    Mol Cancer Ther; 2018 Jan; 17(1):73-83. PubMed ID: 29133622
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. An Essential Role for the tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.
    Stepanova DS; Semenova G; Kuo YM; Andrews AJ; Ammoun S; Hanemann CO; Chernoff J
    Cancer Res; 2017 Sep; 77(18):5026-5038. PubMed ID: 28729415
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Copy number alterations determined by single nucleotide polymorphism array testing in the clinical laboratory are indicative of gene fusions in pediatric cancer patients.
    Busse TM; Roth JJ; Wilmoth D; Wainwright L; Tooke L; Biegel JA
    Genes Chromosomes Cancer; 2017 Oct; 56(10):730-749. PubMed ID: 28597942
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. The torc1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity.
    Rubens JA; Wang SZ; Price A; Weingart MF; Allen SJ; Orr BA; Eberhart CG; Raabe EH
    Neuro Oncol; 2017 Oct; 19(10):1361-1371. PubMed ID: 28582547
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Case of parotid mucoepidermoid carcinoma: Expanding the spectrum of von Hippel-Lindau-related neoplasms.
    Berger MH; Kerr DA; Rangel Filho AE; Sargi ZB
    Head Neck; 2017 Mar; 39(3):E51-E54. PubMed ID: 28006088
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth.
    Kannan A; Lin Z; Shao Q; Zhao S; Fang B; Moreno MA; Vural E; Stack BC; Suen JY; Kannan K; Gao L
    Oncotarget; 2016 Feb; 7(6):6576-92. PubMed ID: 26536665
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Mitf is a master regulator of the v-ATPase, forming a control module for cellular homeostasis with v-ATPase and torc1.
    Zhang T; Zhou Q; Ogmundsdottir MH; Möller K; Siddaway R; Larue L; Hsing M; Kong SW; Goding CR; Palsson A; Steingrimsson E; Pignoni F
    J Cell Sci; 2015 Aug; 128(15):2938-50. PubMed ID: 26092939
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma.
    Studebaker A; Bondra K; Seum S; Shen C; Phelps DA; Chronowski C; Leasure J; Smith PD; Kurmasheva RT; Mo X; Fouladi M; Houghton PJ
    Pediatr Blood Cancer; 2015 Oct; 62(10):1768-74. PubMed ID: 25981859
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs.
    Patwardhan PP; Surriga O; Beckman MJ; de Stanchina E; Dematteo RP; Tap WD; Schwartz GK
    Clin Cancer Res; 2014 Jun; 20(12):3146-58. PubMed ID: 24718867
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. torc1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.
    Corcoran RB; Rothenberg SM; Hata AN; Faber AC; Piris A; Nazarian RM; Brown RD; Godfrey JT; Winokur D; Walsh J; Mino-Kenudson M; Maheswaran S; Settleman J; Wargo JA; Flaherty KT; Haber DA; Engelman JA
    Sci Transl Med; 2013 Jul; 5(196):196ra98. PubMed ID: 23903755
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.